Pfizer's Novel HIV/AIDS Treatment Selzentry™ (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naïve HIV Patients

Patients taking Selzentry, in combination with Combivir® (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism test to screen patients, experienced a 68 percent rate of virologic suppression to undetectable levels, according to the MERIT ES (Reanalysis of the MERIT Study wit

Add to: del.icio.us | Digg